Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Nasus Pharma Ltd's Competitiveness

Name: Nasus Pharma Ltd Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Nasus Pharma Ltd (NSRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/NSRX/competitors                    

                        https://api.csimarket.com/api/v1/companies/NSRX/relationships                    

                        https://api.csimarket.com/api/v1/companies/NSRX/similar                    

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

What's Included in the Financial API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Nasus Pharma Ltd's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Nasus Pharma Ltd	-	-	-	-
High-Confidence Competitors (2)	-
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

NSRX Stock Performance relative to its Competitors

NSRX Competitors (weighted) Percent change over the selected range

Nasus Pharma Ltd's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(0 of 1)

Similar-Size
(1 of 9)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Nasus Pharma Ltd	-58.30 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (1)	40.4%	63.2%
Similar-Size Competitors (9)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Nasus Pharma Ltd's competitor groups requires a Commercial License.

Unlock Full Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

NSRX Stock Performance relative to High-Confidence Competitors

NSRX High-Confidence Competitors (equal-weighted, 2) Percent change over the selected range

NSRX Stock Performance relative to Similar-Size Competitors

NSRX Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Nasus Pharma Ltd's Comment on Competition and Industry Peers

The company operates in the pharmaceutical industry, which is characterized by intense competition and rapid technological change. Its proprietary position relies on patents that may not fully prevent competitors from using the same product candidates for different indications. The company currently has no approved products and is focused on developing NS002 for the emergency treatment of allergic reactions. It may compete with firms that have extensive and well-funded marketing and sales operations. The company faces risks related to the Section 505(b)(2) regulatory pathway, including potential challenges to FDA interpretations that could delay approvals and increase patent litigation risks. Its success depends on completing clinical development, obtaining regulatory approvals, and achieving market acceptance among physicians, patients, and payors. Failure in any of these areas could negatively impact its competitive position and financial condition.

Competitor data is not yet available for Nasus Pharma Ltd.

Nasus Pharma Ltd's Competitors Named by the Company

Competitive relationships identified from Nasus Pharma Ltd reports and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Altamira Therapeutics Ltd	Company report	85%	2022 to 2026	3
Opiant Pharmaceuticals Inc	Company report	85%	2022 to 2026	3

Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Nasus Pharma Ltd's named competitors require a Commercial License.

Unlock Full Access

Methodology: relationships are extracted from Nasus Pharma Ltd reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.